Renovion company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Series A | Alive

Total Raised


Last Raised

$8.1M | 2 yrs ago

About Renovion

Renovion is a pre-clinical stage pharmaceutical company with a therapy for chronic inflammatory airway diseases.

Renovion Headquarter Location

900 MLK Jr. Blvd, Suite A

Chapel Hill, North Carolina, 27514,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Renovion

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Renovion is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Renovion Patents

Renovion has filed 2 patents.

The 3 most popular patent topics include:

  • Antioxidants
  • Cat diseases
  • Dietary supplements
patents chart

Application Date

Grant Date


Related Topics



Human head and neck, Infectious diseases, Inflammations, Syndromes, Cat diseases


Application Date


Grant Date


Related Topics

Human head and neck, Infectious diseases, Inflammations, Syndromes, Cat diseases



Latest Renovion News

Renovion Provides Regulatory Update and Initiation of Clinical Program in Non-CF Bronchiectasis

Apr 26, 2022

April 26, 2022 09:05 AM Eastern Daylight Time CHAPEL HILL, N.C.--( BUSINESS WIRE )--Renovion, Inc., a clinical-stage pharmaceutical company focused on developing treatments for rare, chronic, and serious lung diseases with high unmet needs, announced today that they have received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical trial to investigate ARINA-1 in non-cystic fibrosis bronchiectasis (NCFBE). ARINA-1 is a nebulized therapy that thins mucus and enables mucus clearance from the lungs while decreasing pathological inflammation. NCFBE is characterized by a vicious and chronic cycle of thick, suffocating mucus, inflammation, and infection that results decreased quality of life. There are no FDA-approved treatment options to decrease mucus viscosity and improve mucus clearance in NCFBE. The ARINA-1 trial will be the first of its kind in this patient population and will enroll from sites across the US. “The clearance of the IND for ARINA-1 use in NCFBE is a significant regulatory milestone for Renovion that allows us to advance our clinical development strategy. We are excited to start participant recruitment for NCFBE trial in Q2 2022 and continue our clinical development with trials in lung transplant and non-tuberculosis mycobacteria pulmonary disease starting later this year,” said Carolyn Durham, PhD, Chief Scientific Officer of Renovion, Inc. Renovion, Inc. Renovion is a clinical stage pharmaceutical company focused on developing ARINA-1, novel nebulized therapy delivered to the lungs to treat pulmonary diseases. ARINA-1 clears mucus and reduces damaging inflammation in the airways to restore lung health. ARINA-1 is poised to start clinical trials in chronic inflammatory airways diseases, including non-cystic fibrosis (CF) bronchiectasis (NCFBE) and chronic obstructive pulmonary disease (COPD). The Renovion team has in-depth experience in drug development with extensive scientific expertise in chronic pulmonary conditions and inflammation. For more information on Renovion, visit or follow Renovion on Twitter . Contacts

Renovion Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Renovion Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.